Key Documents

View All Documentation

C2174005

Cilazapril impurity D

Name: Cilazapril impurity D
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(1S,9S)-9-{[(R)-1-Ethoxycarbonyl-3-phenylpropyl]amino}-10- oxo-octahydro-6H-pyridazino[1,2a][1,2]diazepine-1-carboxylic acid

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₂H₃₁N₃O₅

CAS Number:

106928-09-0

Molecular Weight:

417.50

MDL number:

MFCD00078109

NACRES:

NA.24

UNSPSC Code:

41116107

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

grade

pharmaceutical primary standard

API family

cilazapril

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Description

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Cilazapril impurity D EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Short-term effects of cilazapril and atenolol on P-wave dispersion in patients with hypertension.

Mustafa Tuncer et al.

Advances in therapy, 25(2), 99-105 (2008-02-26)

P-wave dispersion (PWD) has been shown to be a non-invasive electrocardiographic predictor for development of atrial fibrillation (AF). Thus, it may be possible to decrease AF risk through improvement in PWD. Our objective was to compare the effects of cilazapril

Blood pressure and cardiorenal responses to antihypertensive therapy in obese women.

Eduardo Cantoni Rosa et al.

Arquivos brasileiros de endocrinologia e metabologia, 52(1), 65-75 (2008-03-18)

Blood pressure (BP) and target organ responses to antihypertensive drugs are not well established in hypertensive obese patients. This study is aimed at evaluating the effects of obesity and adiposity distribution patterns on these responses. 49 hypertensive obese women were

Reversible posterior encephalopathy syndrome in systemic lupus erythematosus and lupus nephritis.

Yan-Xing Zhang et al.

Internal medicine (Tokyo, Japan), 47(9), 867-875 (2008-05-03)

Reversible posterior encephalopathy syndrome (RPES) is a clinical entity characterized with headache, nausea, vomiting, seizures, consciousness disturbance, and frequently visual disorders associated with neuroradiological findings, predominantly white matter abnormalities of the parieto-occipital lobes. The central nervous system manifestations of systemic

View All Related Papers

Global Trade Item Number

SKU	GTIN
C2174005	04061833475263